Shenhai Wei1, Jintao Tian2, Xiaoping Song2, Bingqun Wu2, Limin Liu3. 1. Department of Thoracic Surgery, First Hospital of Tsinghua University, No. 6, the First Road, Jiuxianqiao, Chaoyang District, Beijing, 100016, People's Republic of China. weishenh@qq.com. 2. Department of Thoracic Surgery, First Hospital of Tsinghua University, No. 6, the First Road, Jiuxianqiao, Chaoyang District, Beijing, 100016, People's Republic of China. 3. Department of Physiology, Capital Medical University, Beijing, 100069, People's Republic of China.
Abstract
PURPOSE: To investigate the probability of death (POD) from any causes by time after diagnosis of non-small cell lung cancer (NSCLC) and the factors associated with survival for NSCLC patients. METHODS: A total of 202,914 patients with NSCLC from 2004 to 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The overall survival (OS) and lung cancer-specific survival (LCSS) were calculated and POD from any causes at different time periods after diagnosis was explored. The predictive factors for OS, LCSS and survival from non-lung cancer deaths were investigated using multivariate analysis with Cox proportional hazards regression and competing risk regression analysis. RESULTS: The 5- and 10-year OS were 20.4% and 11.5%, accordingly that for LCSS were 25.5% and 18.4%, respectively. Lung cancer contributed 88.3% (n = 128,402) of the deaths. The POD from lung cancer decreased with time after diagnosis. In multivariate analysis, advanced age and advanced stage of NSCLC were associated with decreased OS and LCSS. Comparing to no surgery, any kind of resection conferred lower risk of death from lung cancer and higher risk of dying from non-lung cancer conditions except lobectomy or bilobectomy, which was associated with lower risk of death from both lung cancer and non-lung cancer conditions. CONCLUSIONS: Most of the patients with NSCLC died from lung cancer. Rational surveillance and treatment policies should be made for them. Early stage and lobectomy or bilobectomy were associated with improved OS and LCSS. It is reasonable to focus on early detection and optimal surgical treatment for NSCLC.
PURPOSE: To investigate the probability of death (POD) from any causes by time after diagnosis of non-small cell lung cancer (NSCLC) and the factors associated with survival for NSCLCpatients. METHODS: A total of 202,914 patients with NSCLC from 2004 to 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The overall survival (OS) and lung cancer-specific survival (LCSS) were calculated and POD from any causes at different time periods after diagnosis was explored. The predictive factors for OS, LCSS and survival from non-lung cancer deaths were investigated using multivariate analysis with Cox proportional hazards regression and competing risk regression analysis. RESULTS: The 5- and 10-year OS were 20.4% and 11.5%, accordingly that for LCSS were 25.5% and 18.4%, respectively. Lung cancer contributed 88.3% (n = 128,402) of the deaths. The POD from lung cancer decreased with time after diagnosis. In multivariate analysis, advanced age and advanced stage of NSCLC were associated with decreased OS and LCSS. Comparing to no surgery, any kind of resection conferred lower risk of death from lung cancer and higher risk of dying from non-lung cancer conditions except lobectomy or bilobectomy, which was associated with lower risk of death from both lung cancer and non-lung cancer conditions. CONCLUSIONS: Most of the patients with NSCLC died from lung cancer. Rational surveillance and treatment policies should be made for them. Early stage and lobectomy or bilobectomy were associated with improved OS and LCSS. It is reasonable to focus on early detection and optimal surgical treatment for NSCLC.
Entities:
Keywords:
Cause of death; Lung cancer-specific survival; Non-small cell lung cancer; Overall survival
Authors: N G Zaorsky; T M Churilla; B L Egleston; S G Fisher; J A Ridge; E M Horwitz; J E Meyer Journal: Ann Oncol Date: 2017-02-01 Impact factor: 32.976
Authors: Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: William L Read; Ryan M Tierney; Nathan C Page; Irene Costas; Ramaswamy Govindan; Edward L J Spitznagel; Jay F Piccirillo Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Christos Alexiou; David Beggs; Patrick Onyeaka; Kostas Kotidis; Sudip Ghosh; Lynda Beggs; David N Hopkinson; John P Duffy; W Ellis Morgan; Gaetano Rocco Journal: Ann Thorac Surg Date: 2003-10 Impact factor: 4.330
Authors: Yihui Du; Yingru Zhao; Grigory Sidorenkov; Geertruida H de Bock; Xiaonan Cui; Yubei Huang; Monique D Dorrius; Mieneke Rook; Harry J M Groen; Marjolein A Heuvelmans; Rozemarijn Vliegenthart; Kexin Chen; Xueqian Xie; Shiyuan Liu; Matthijs Oudkerk; Zhaoxiang Ye Journal: Cancer Biol Med Date: 2019-02 Impact factor: 4.248
Authors: Helmneh M Sineshaw; Ahmedin Jemal; Kimmie Ng; Raymond U Osarogiagbon; K Robin Yabroff; Kathryn J Ruddy; Rachel A Freedman Journal: JNCI Cancer Spectr Date: 2019-04-15
Authors: Andrea Santarelli; Marco Mascitti; Lucio Lo Russo; Davide Sartini; Giuseppe Troiano; Monica Emanuelli; Lorenzo Lo Muzio Journal: Int J Mol Sci Date: 2018-03-24 Impact factor: 5.923